Association of alprazolam with major cardiovascular events in patients with hypertension

doi:doi.org/10.1111/jep.13254

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/21692

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/21692

Title:	Association of alprazolam with major cardiovascular events in patients with hypertension
Authors:	Chao-Bin Yeh;Ming-Che Tsai;Ying-Hock Teng;Min-Sho Ku;Jing-Yang Huang;Bo-Yuan Wang;Chia-Ling Tai;Edy Kornelius;Sai-Wai Ho
Keywords:	alprazolam;hypertension;major adverse cardiovascular events;retrospective cohort study;stroke.
Date:	2020-08-06
Issue Date:	2021-08-26T01:54:46Z (UTC)
Publisher:	John Wiley & Sons, Inc.
Abstract:	Rationale: Anxiety is a mediator for emotional reactivity and acute blood pressure elevations, which are associated with an increased risk of cardiovascular death. Alprazolam is a common medication for anxiolysis. We hypothesized that alprazolam usage can reduce the risk of major adverse cardiovascular events (MACEs) in patients with hypertension. Methods: A retrospective cohort study was performed using datasets from Taiwanese Health and Welfare Data. Patients with hypertension were divided into exposed (Alprazolam-exposed) and control groups (non-Alprazolam-exposed) with 1:1 propensity score matching. The study endpoint was the occurrence of MACE. Adjusted hazard ratio (aHR) of MACE risk was estimated using the multiple Cox proportional hazard model. Age-stratified analysis was performed to evaluate the interaction of age and alprazolam use with MACEs. Results: The study cohort consisted of 335 517 alprazolam-exposed patients and 1:1 PSM controls. The mean age was 63.62 ± 12.71 years in the Alprazolam-exposed population. Alprazolam exposure was significantly associated with reduced risk of MACEs (aHR = 0.965, 95% CI = 0.954-0.977), including ischemic stroke (aHR = 0.958, 95% CI = 0.940-0.976), hemorrhagic stroke (aHR = 0.856, 95% CI = 0.821-0.892), myocardial infarction (aHR = 0.933, 95% CI = 0.900-0.968), sudden cardiac death (aHR = 0.955, 95% CI = 0.916-0.996), and all-cause mortality (aHR = 0.921, 95% CI = 0.909-0.932). In the age-subgroup analysis, alprazolam showed the greatest risk reduction effect in hemorrhagic stroke for patients aged <65 years (aHR = 0.779, 95% CI = 0.727-0.835). Conclusion: Alprazolam usage in patients with hypertension was associated with a slightly reduced risk of MACEs and all-cause mortality, and up to 22% reduced risk of hemorrhagic stroke was observed in alprazolam users aged <65 years.
URI:	https://ir.csmu.edu.tw:8080/handle/310902500/21692
Relation:	J Eval Clin Pract , Volume26, Issue3, Pages 983-991
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

File	Description	Size	Format
jep.13254.pdf		1225Kb	Adobe PDF	220	View/Open

View Licence

Loading...